Inferring Somatic Mutation Rates Using the Stop-Enhanced Green Fluorescent Protein Mouse by �끂�썝�긽
Copyright  2007 by the Genetics Society of America
DOI: 10.1534/genetics.106.069310
Inferring Somatic Mutation Rates Using the Stop-Enhanced Green
Fluorescent Protein Mouse
Simon Ro* and Bruce Rannala†,1
*Department of Medical Genetics, University of Alberta, Edmonton, Alberta T6G 2H7, Canada and †Genome Center and
Section of Evolution and Ecology, University of California, Davis, California 95616
Manuscript received December 6, 2006
Accepted for publication June 13, 2007
ABSTRACT
A new method is developed for estimating rates of somatic mutation in vivo. The stop-enhanced green
fluorescent protein (EGFP) transgenic mouse carries multiple copies of an EGFP gene with a premature
stop codon. The gene can revert to a functional form via point mutations. Mice treated with a potent
mutagen, N-ethyl-N-nitrosourea (ENU), and mice treated with a vehicle alone are assayed for mutations in
liver cells. A stochastic model is developed to model the mutation and gene expression processes and
maximum-likelihood estimators of the model parameters are derived. A likelihood-ratio test (LRT) is
developed for detecting mutagenicity. Parametric bootstrap simulations are used to obtain confidence
intervals of the parameter estimates and to estimate the significance of the LRT. The LRT is highly
significant (a , 0.01) and the 95% confidence interval for the relative effect of the mutagen (the ratio of
the rate of mutation during the interval of mutagen exposure to the rate of background mutation) ranges
from a minimum 200-fold effect of the mutagen to a maximum 2000-fold effect.
SOMATIC mutation is a process of fundamentalimportance in many human diseases such as cancer
(Hanahan and Weinberg 2000; Ponder 2001; Yang
et al. 2003); it may also play a role in biological processes
suchasaging,althoughthis iscontroversial(Sedelnikova
et al. 2004; Gorbunova and Seluanov 2005). Many
factors influence the rates (and patterns) of somatic
mutation. Some influences are environmental (e.g., ex-
posure to chemicals and UV-radiation, etc.) and others
are genetic (e.g., GC content of DNA sequences, muta-
tions in DNA repair genes, etc.). To uncover the im-
portant factors influencing rates of somatic mutation
(and by extension, rates of cancer, etc.) in a mammalian
system, improved mutation detection systems are re-
quired for estimating rates of somatic mutation in cells
exposed to potential environmental, or genetic, risk
factors.
In the early 1990s, transgenic mouse mutation de-
tection systems were developed by inserting either the
lacZ or the lacI bacterial transgene into mice (Gossen
et al. 1989; Kohler et al. 1991). Such transgenic muta-
tion detection systems have been widely used for mea-
suring mutant frequency (i.e., the relative number of
mutants in a population of cells) after treatment with
various mutagenic agents in different tissues (Dean et al.
1999; Suzuki et al. 1999; Thybaud et al. 2003). The
validity of these systems for studying somatic mutations
in mammals has been questioned, however, because
many features of the bacterial lacZ and lacI genes, the
target genes for mutations, are typically prokaryotic and
the systems therefore may not represent the character-
istic patterns of mutations one would expect to see in
mammalian genes (Skopek 1998). Another shortcom-
ing is that overall mutant frequency can be influenced by
various nonmutagenic factors such as the clonal expan-
sion of mutant cells, the sampling time following treat-
ment when the mutation assay is performed, etc. (Heddle
1999a; Sun and Heddle 1999; Thybaud et al. 2003).
Estimation of the mutation rate (i.e., the rate at which
mutations arise, rather than the frequency of mutants) is
desirable in mutation studies because the mutation rate
better reflects the underlying mutational mechanisms
and addresses mutagenicity questions more directly than
the mutant frequency (Drake 1970; Thompson et al.
1998).
Recently, a novel transgenic mouse system has been
developed that carries an enhanced green fluorescent
protein (EGFP) gene containing a premature stop codon
(referred to as the stop-EGFP gene) and the wild-type
enhanced blue fluorescent protein (EBFP) gene. This
system has been applied to trace clonal cell lineages
in vivo (Ro 2004; Ro and Rannala 2004, 2005). In the
stop-EGFP mouse, a cell having undergone a mutation
at the premature stop codon within the stop-EGFP gene
(and its descendant cells) expresses functional revertant
EGFP, thus allowing clonal cell lineages to be traced
using fluorescence imaging. Because the stop-EGFP gene
can function as a reporter for mutation and green
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fluorescent mutant cells generated by revertant mutations
at the premature stop codon within the stop-EGFP gene
can be easily detected using fluorescence imaging, the
stop-EGFP system has the potential to be utilized as an
in vivo mutation detection system. Several character-
istics of the stop-EGFP mouse are anticipated to be ad-
vantageous for in vivo mutation studies. First, the EGFP
gene has been genetically modified to enhance mam-
malian characteristics (Yang et al. 1996) and thus the
stop-EGFP gene is expected to reveal mutational char-
acteristics typical of mammalian genes. Second, the
stop-EGFP gene is transcribed in cells (Ro and Rannala
2004), which will further enhance the similarity to
mammalian endogenous genes. Third, because the EBFP
gene, colocalized with the EGFP gene, provides a target
nucleotide for GC / AT transitions, the stop-EGFP
system allows all possible point mutations to be detected
that may arise by either transitions (AT/GC and GC/
AT) or transversions (AT/ TA, AT/ CG, GC/ TA,
and GC/ CG) (see Ro and Rannala 2004).
Finally, independent mutations in a tissue of the stop-
EGFP mouse can be counted by detecting green fluo-
rescent colonies (clonal cell lineages originating from
mutant cells), facilitating estimation of mutation rate.
Here, we use the stop-EGFP system to study somatic
mutation rates. We treated the stop-EGFP mouse with
N-ethyl-N-nitrosourea (ENU) at a dose of 150 mg/kg
body weight and examined the mutagenicity of the sub-
stance in the liver. Mutagenesis in live mammals is a
complex process that involves DNA damage incurred by
exposure to a mutagen, fixation of mutations, transcrip-
tion from a mutant gene, expression of mutant pheno-
types, etc. (Heddle 1999b). A mutation assay carried out
at an earlier time point might underestimate the actual
mutagenic potential of a substance because of insuffi-
cient expression of the mutant phenotype from some
mutant cells (Sun and Heddle 1999). To better evaluate
the mutagenic potential of a substance using the stop-
EGFP mouse system we carried out a time-course study of
mutations observed in the left caudal liver lobe after
exposure to ENU. On the basis of estimation by maxi-
mum likelihood using a novel statistical model and
inference procedure developed in this study, we com-
pared the rate of mutation (in the liver) induced by ENU
with the background rate and also estimated the waiting
time until a revertant phenotype is expressed in a cell.
MATERIALS AND METHODS
Preparation of ENU solution: The ENU solution was
prepared in a type IIB2 biosafety cabinet that exhausts 100%
to the outside. A vial containing 1 g of ENU powder was
purchased (ISOPAC; Sigma, St. Louis). A 10-ml quantity of
95% ethanol was injected into a vial through the rubber
injection port and ENU was dissolved by gentle shaking of the
vial. A 90-ml quantity of phosphate–citrate (0.1 m sodium
phosphate and 0.05m sodium citrate, pH 5.0) was added to the
ENU solution and mixed by inverting and shaking the vial.
Animal experiments: All experiments using live mice were
performed in compliance with the recommendations of the
Canadian Council on Animal Care and have been approved by
the Health Sciences Animal Policy and Welfare Committee of
the University of Alberta.
Animal treatment: The optical density (OD) of the ENU
solution at 398 nm was measured immediately prior to in-
jection to precisely determine the concentration of the ENU
solution. A concentration of 1 mg/m1 of ENU corresponds to
OD 0.72 at 398 nm ( Justice et al. 2000). Only male mice were
used for this study. Mice were anesthetized by inhalation of
isoflurane gas prior to injection. ENU was administered in-
traperitoneally at a dose of 150 mg/kg body weight. Control
mice were injected intraperitoneally with vehicle (9.5% etha-
nol in phosphate–citrate buffer, see above) in a volume of
20 ml/kg body weight.
Mutation assay: For mutation assay, a mouse was killed by
CO2 asphyxiation and perfused with 10 ml of saline followed
by 10 ml of 4% paraformaldehyde. The liver was removed from
the mouse and stored in 4% paraformaldehyde at 4 with
gentle agitation for 11 hr. After fixation, the organ was trans-
ferred to PBS with 1 mmMgCl2 and stored at 4 overnight. The
organ was sectioned into slices (100 mm in thickness) using a
vibratome (VT1000S; Leica, Deerfield, IL). Each slice was then
transferred to a 24-well plate containing PBS with 1 mm MgCl2
and stored until the imaging experiment. At least 4 hr before
imaging, slices were transferred to microscopic slides for
mounting. Ultrapure glycerol (Invitrogen, San Diego) and
103 PBS were mixed with a ratio of 9:1 and used as mounting
media. Slices were illuminated by use of a 50-W mercury lamp
and scanned using a Zeiss Axiovert 200M inverted microscope
with a 103 F-Fluar lens (NA 0.5) and LP 520 emission filter
(Carl Zeiss, Thornwood, NY). Images of green fluorescent
cells were collected with a confocal laser scanning microscope
(LSM 510 NLO, software version 3.2; Carl Zeiss) mounted on
the Zeiss Axiovert 200M inverted microscope with a 253multi-
immersion F-Fluar lens (NA 0.8). EGFP was excited with the
488-nm laser line and a band-pass filter (505–530 nm wave-
length) was used for detecting emissions from EGFP.
49,6-Diamidino-2-phenylindole staining and colocalization
of nuclei: Several slices containing EGFP signals were selected
and used to verify colocalization of 49,6-diamidino-2-phenyl-
indole (DAPI)-stained nuclei and bright EGFP signals within
mutant cells. Slices were incubated for 30 min at room tem-
perature in a PBS solution containing 1 mg/ml of DAPI. Slices
were then briefly washed with PBS and dehydrated by storing
them in 30, 50, 60, 70, 90, 100% ethanol, serially for 5 min at
each step. Slices were then mounted in methyl salicylate. The
DAPI-stained EGFP-expressing cells were imaged with a 253
multi-immersion F-Fluar lens (NA 0.8) on a confocal laser
scanning microscope (LSM 510 NLO, software version 3.2;
Carl Zeiss), using the 488-nm laser line to activate EGFP and a
two-photon laser of 760 nm to activate DAPI-stained DNA.
Estimation of the total number of cells in each lobe: The
total number of cells in the left caudal liver lobe of each mouse
was estimated by multiplying the volume of each lobe by the
total cell number in a unit volume. To calculate the volume,
the whole area of each slice (100mm in thickness, see above) of
the lobe was imaged by the ‘‘Tile scan’’ function using a mo-
torized scanning stage of a confocal laser scanning microscope
(LSM 510 NLO, software version 3.2; Carl Zeiss) with a 2.53
Fluar lens (NA 0.12). Autofluorescence in slices was activated
with the 488-nm laser line and detected using a band-pass filter
(535- to 590-nm wavelength). The total area of each slice was
then measured using MetaMorph software (version 6.26;
Molecular Devices, Menlo Park, CA). To calculate the total
cell number in a unit volume, randomly chosen 1003 100 mm
areas (15 different areas of a liver slice stained with DAPI) were
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scanned along the z-axis and all nuclei contained in this
volume were imaged with a 253multi-immersion F-Fluar lens
(NA 0.8) on a confocal laser scanning microscope (LSM 510
NLO, software version 3.2; Carl Zeiss) using 760 nm as
excitation light. The number of total nuclei in the specified
volume was counted using the spot-counting module of Imaris
software (version 4.2, Bitplane AG).
THEORY
To model the process of somatic mutation in un-
treated mice and mice treated with a potential mutagen,
we develop a simple three-parameter model. Let the
observed data be represented as a vector X¼ {Xi}, where
Xi is the number of independent stop-EGFP mutations
observed for mouse i and i ¼ 1, . . . , n. The observed
(and/or experimentally fixed) model parameters (for
mouse i) are the total number of cells examined, Ni, the
age of the mouse when the mutation assay is performed,
TAi , and the age at time of exposure (to either the
mutagen or the vehicle), TEi , both in units of days. The
unobserved parameters to be estimated are the back-
ground rate of mutation (per cell, per day),m, the rate of
mutation during exposure to the mutagen, d, and the
expected time (in units of days) until a mutant cell
begins expressing a revertant protein, 1/l.
It is natural to assume that mutation processes in in-
dividual mice are independent, and thus we first develop
the probabilistic model for a single mouse (dropping
subscripts for simplicity). The stochastic model we de-
velop assumes background mutations arise according to
a homogenous Poisson process with rate m per cell; the
expected number of mutations per unit time is therefore
mN. Time-dependent mutation rates could be easily
incorporated, but the data are likely insufficient to
estimate the parameters of a more complex model. At
time-pointTE, a spike in the mutation rate occurs so that
the expected number of mutations during the period of
mutagen exposure is dN.
Background mutation: We first consider the model of
background mutation. Let Y be the total number of
mutations arising on the time interval (0, TA). The
expectation of Y is EðY Þ ¼ mNTA: We assume that no
more than one mutation occurs in a cell, which is rea-
sonable whenmTA ¼ EðY Þ=N is very small. The marginal
distribution of the age at which any given mutation arises
is uniform on (0, TA). We assume that the waiting time
until a revertant protein is expressed in a cell, given that
a mutation has occurred, follows an exponential distri-
bution with mean 1/l. Conditional on a mutation
having occurred in a cell, the probability that it is
expressing the revertant protein at time TA is
p ¼
ðTA
t¼0
ðTA
y¼t
1
TA
lelðytÞdy dt ¼ 11 e
lTA  1
lTA
:
The probability that at time TA, nB cells are expressing
revertant proteins that arose via the background muta-
tion process is then
PrðnBÞ¼
X‘
Y¼nC
emNTA ðmNTAÞY
Y !
3
Y
nB
 
3 pnB 3 ð1  pÞYnB
¼ 1
nB!
ðmNTApÞnBemNTAp :
In deriving this result, we assume that the number of
cells is stationary, but this can be easily relaxed by al-
lowing the number of cells to be a function of time N(t)
and using a nonhomogenous Poisson model (to ac-
count for changes in cell number in early development,
for example).
Exposure to a mutagen: It is assumed that the period
of exposure to a mutagenic substance is of short dura-
tion (e.g., a few days), which is true for the mutagen
(ENU) that we use in this study. This implies that mu-
tations induced by the mutagen arise only at time TE
(e.g., the day on which the treatment is applied). The
probability that a mutation arising at time TE is ex-
pressed as a revertant protein at time TA (assuming an
exponential distribution for the waiting time to expres-
sion) is
q ¼
ðTA
y¼TE
lelðyTEÞdy ¼ 1  elðTETAÞ;
and the probability that nE mutations are induced by the
mutagen and are expressing revertant protein at time
TA is
PrðnEÞ ¼
X‘
Y¼nE
edN ðdN ÞY
Y !
3
Y
nE
 
3 qnE 3 ð1  qÞYnE
¼ 1
nE!
ðdNqÞnE edNq :
The likelihood: The observed data for mouse i are the
total number of mutations, which are the sum of back-
ground mutations, nBi ; and mutagen-induced muta-
tions, nEi ; namely Xi ¼ nBi 1nEi : This is a convolution of
two Poisson distributions, which is also a Poisson
distribution,
PrðXi jm; d; lÞ ¼ 1
Xi!
bXii e
bi ;
but with an expectation, bi, that is the sum of the
expectations of the two variables,
bi¼ EðXiÞ¼ EðnBi Þ1 EðnEi Þ
¼ mNi TAi1
elTAi  1
l
 
1 dNi 1  elðTEiTAi Þ
 
:
Now let k be the number of mice treated with the
mutagen and n  k be the number of mice treated with
the vehicle alone. Order the labels of the mice such that
if mouse i is treated with the vehicle alone then i# n k.
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For the mice treated only with the vehicle (controls), we
assume that d ¼ 0. The joint likelihood is
Lðm; d; l jXÞ
¼
Ynk
i¼1
PrðXi jm; d ¼ 0; lÞ3
Yn
j¼nk1 1
PrðXj jm; d; lÞ:
The log-likelihood was numerically maximized using the
R statistics package (http://r-project.org) to obtain joint
maximum-likelihood estimates (MLEs) of parameters
m, d, and l. It is possible to analytically calculate the
gradients of the likelihood and the Hessian matrix (the
matrix of partial second derivates) and we therefore
used the R package ‘‘trust’’ that uses gradients and
Hessians to carry out optimization (http://www.stat.umn.
edu/geyer/trust/). Functions were written in R to
simulate samples from this likelihood allowing the
parametric bootstrap to be applied to generate confi-
dence intervals (and a variance–covariance matrix) for
the estimates without appealing to asymptotic theory. An
R script implementing these procedures is freely avail-
able from http://rannala.org.
Likelihood-ratio test of mutagenicity: To test the
mutagenicity of a substance we propose a likelihood-
ratio test (LRT). Under the null hypothesis, exposure to
a substance does not produce an increased rate of
mutation and d ¼ 0 in both control and treated mice.
Under the alternative hypothesis, d ¼ 0 in control mice
and d. 0 for treated mice. The LRT statistic is 2log L,
where L is
L ¼ Lðmˆ; dˆ; lˆ jXÞ
Lðmˆ; d ¼ 0; lˆ jXÞ;
where the numerator is the likelihood of the data with
the MLEs obtained by maximizing over the three
parameters jointly and the denominator is the likeli-
hood of the data with MLEs obtained jointly for m and l
with d¼ 0. The test statistic should follow an asymptotic
x2-distribution with 1 d.f. However, because d ¼ 0 is a
boundary condition this is not guaranteed and so we
also calculated significance using a parametric boot-
strap approach (simulating data under the null hypoth-
esis). The estimate of m appears to be insensitive to the
value of l for biologically reasonable values of the
waiting time to expression (e.g., l . 0.01 and l ,
100). Fixing l it is possible to obtain an analytical
expression for the MLE of m,
mˆ ¼
P
XiPðNi ½TAi 1 ðelTAi  1Þ=lÞ:
This expression was used to obtain MLEs of m under the
null model for the LRT and the C.I. for m was obtained
by parametric bootstrap simulations.
RESULTS
Detection of mutations in the left caudal liver lobe:
Mutations in the liver of the stop-EGFP mouse were
directly observed in situ using fluorescence imaging.
The assay is based on identifying mutant cells having
undergone a revertant mutation at the premature stop
codon within the stop-EGFP gene, which would express
a functional EGFP revertant. For mutation assay, slices
from the left caudal liver lobe were scanned using a
fluorescence microscope. Mutant cells exhibited bright
green fluorescence when illuminated with the excita-
tion light of 488 nm and were easily identified (Figure
1). Mutant cells contained what appeared to be brighter
nuclei. The bright spots were confirmed to be nuclei by
use of DAPI staining (Figure 1, A and B).
A cell having undergone a mutation at the premature
stop codon and its clonal descendant cells will constitute
a green fluorescent patch (i.e., a mutant colony), which
can be regarded as a single mutation. Thus, the number
of independent mutations in the left caudal liver lobe of
each mouse can be determined by counting the number
of green fluorescent colonies in the lobe.
Time-course study of mutations in livers of ENU-
exposed and control mice: We performed a mutation
assay on the livers of 10 stop-EGFP mice at 5 months
postvehicle treatment (seematerials andmethods) as
a control. The number of mutations and estimated total
number of cells in the liver lobe of each mouse are
shown in Table 1 (ID nos. 1–10) as well as the ages of
mice at the time of mutation assay. The data were used to
estimate the rate of spontaneous mutation in the liver.
Consistent with our previous data, a mutant colony
Figure 1.—Green fluorescent mutant cells in the liver. (A
and B) Merged images of EGFP signals and DAPI signals of mu-
tant cells detected in the liver. The bright green fluorescent sig-
nals within these cells are colocalized with the DAPI-stained
nuclei. (C and D) Images of EGFP signals of mutant hepato-
cytes. Bars, 10 mm.
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carrying more than two nuclei has not been detected in
the liver (Ro and Rannala 2004), and this may reflect
the slow rate of cell proliferation in this tissue.
We also performed a mutation assay in the liver at
different time points following exposure to ENU to in-
vestigate how the number of observed mutations changes.
Twelve stop-EGFP mice were treated with ENU at a dose
of 150 mg/kg body weight and mice were killed at 1, 3,
and 7 months post-ENU administration. The number of
observed mutations and estimated total number of cells
in the left caudal liver lobe of each mouse are shown in
Table 1 (see ID nos. 11–22). These data were used to
estimate the rate of mutation induced by ENU in the
liver.
The data suggest that a longer waiting time between
exposure and the mutation assay results in more muta-
tions (on average) presumably because some cells carry-
ing a mutation may not exhibit the mutant phenotype
due to insufficient time to express a revertant protein. At
1 month post-ENU administration, few mutations were
found in the ENU-treated liver (Table 1). We speculate
the time period of 1 month after treatment with ENU
might be too short for mutant cells in the liver to
commonly exhibit the mutant phenotype. Expression of
the mutant phenotype in the liver of a stop-EGFP mouse
is a complex multistage process that requires fixation of
a mutation, transcription from a mutant copy of the
stop-EGFP gene, accumulation of mutant mRNA con-
taining no premature stop codon, and protein synthesis
from the mutant mRNA at a level sufficient for detection
under a fluorescence microscope (Heddle 1999b).
These processes may take months in the liver (Douglas
et al. 1996; Wang et al. 2004).
Estimates of parameters: On the basis of the exper-
imental data given in Table 1 and the model developed
in this study (see theory), we estimated the back-
ground mutation rate per cell per day (m), a spike in the
mutation rate (per cell per day) due to the treatment
with ENU (d), the ratio of the two parameters (R¼ d/m)
that quantifies the relative effect of the mutagen, and
the waiting time until a revertant protein is expressed in
a cell (1/l). The marginal log-likelihoods of each of the
three parameters (obtained by setting the remaining
two parameters at their MLE values) are shown in Fig-
ure 2. The MLEs and associated 95% confidence in-
tervals of the parameters are given in Table 2. The
confidence intervals are based on a parametric boot-
strap using 1000 simulated data sets. The LRT statistic is
2 log L ¼ 21.04, which is significant at the a ¼ 0.01
level based on either a x2-distribution with 1 d.f. or a
parametric bootstrap analysis (see Figure 3). Thus, the
treatment with ENU appears to elevate the mutation
rate significantly over the rate of spontaneous mutation.
This is also clear from the 95% confidence interval of
TABLE 1
Mutation counts
Mouse ID TE TA No. mutations No. cells Treatment/control
1 69 220 0 2.07 3 108 Control
2 231 382 0 1.52 3 108 Control
3 82 233 0 1.60 3 108 Control
4 57 208 0 1.43 3 108 Control
5 204 355 1 1.80 3 108 Control
6 57 208 1 1.21 3 108 Control
7 82 233 2 1.74 3 108 Control
8 69 220 2 1.41 3 108 Control
9 284 435 2 1.58 3 108 Control
10 284 435 4 1.71 3 108 Control
11 158 188 0 1.16 3 108 Treatment
12 55 85 2 1.06 3 108 Treatment
13 55 85 0 1.02 3 108 Treatment
14 158 188 0 1.23 3 108 Treatment
15 71 163 2 1.25 3 108 Treatment
16 139 231 3 1.70 3 108 Treatment
17 101 193 7 1.53 3 108 Treatment
18 62 276 0 1.31 3 108 Treatment
19 71 285 2 1.39 3 108 Treatment
20 71 285 1 1.30 3 108 Treatment
21 96 310 12 1.61 3 108 Treatment
22 144 358 6 1.62 3 108 Treatment
Mutation counts were obtained by imaging the left caudal liver lobe of mice treated with a mutagen ENU
(treatment) or the vehicle alone (control). TE is the time of exposure (to ENU or vehicle) in days since birth, TA
is the time at which a mouse was imaged (in days since birth). The number of mutations (column 4) is the total
number of mutant EGFP-expressing colonies observed and the number of cells (column 5) is the total number
of liver cells scanned.
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R that ranges from a minimum 200-fold effect to a
maximum 2000-fold effect of the mutagen on mutation
rates. It is interesting to note that although the mutation
rate estimates themselves are quite imprecise, the rel-
ative mutagenic effect of ENU is very strongly supported
by the data.
DISCUSSION
In this study, we have applied the stop-EGFP mouse to
quantify the numbers of independent mutations having
arisen in vivo and to estimate rates of somatic mutation
in the liver. Our analysis using stop-EGFP transgenic
mice allowed us to determine the mutagenic effect of
ENU on liver cells. The study suggests that an1000-fold
increase over the spontaneous mutation rate was in-
duced by treatment with ENU (2.73 108 vs. 3.73 1011
per cell per day). Previously, mutation studies using
transgenic mouse systems carrying a bacterial transgene
showed only modest increases in mutant frequencies in
ENU-treated liver over control (Collaborative Study
Group for the Transgenic Mouse Mutation Assay
Mammalian Mutagenesis Study Group of the Envi-
ronmentalMutationSocietyof Japan 1996; Yamada
et al. 1999). In many cases, such studies have simply
compared mutant frequencies between treated and
control groups at the time of the experimental end
point. This approach can underestimate the specific
mutagenic effect of ENU because mutant cells having
arisen due to spontaneous mutations over the lifetime of
a mouse might outnumber mutants generated by ENU
treatment during a very short time period. To specifically
determine the mutagenic effect of ENU we estimated
the rate of mutation induced by ENU during the time
interval of the ENU administration and compared this
rate with the background mutation rate based on the
model developed in this study. ENU is very unstable
under physiological conditions with a half-life of ,1 hr
at pH 6.8–7.3 (Winter and Gearhart 2001) and thus it
is expected that most of the mutagen will have degraded
within 1 day and mutations induced by treatment with
ENU will most likely arise within a single day following
TABLE 2
Parameter estimates
Model Parameter MLE 95% C.I. logL
H0: d ¼ 0 m 5.6 3 1011 (3.9 3 1011, 7.1 3 1011) 8.174
H1: d . 0 m 3.7 3 1011 (1.6 3 1011, 1.3 3 107) 2.346
d 2.7 3 108 (1.3 3 108, 1.1 3 104)
R ¼ d/m 737 (311, 1956)
1/l 106 (13, 8 3 106)
Maximum-likelihood estimates of parameters and 95% confidence intervals (obtained using a parametric
bootstrap procedure) are shown. The parameters are m, the spontaneous rate of mutation per site, d, the rate
of mutation per site induced by treatment, and 1/l, the average waiting time (in units of days) until an EGFP
mutant cell expressed revertant protein. Note that because proportionality constants that do not affect infer-
ences have been removed from the log-likelihood function, logL may be positive.
Figure 2.—Marginal log-likelihood (logL) curves for the three parameters l, d, and m obtained using the stop-EGFP mouse data
given in Table 1. The marginal logL of each parameter is plotted with the remaining two parameters fixed at their maximum-
likelihood estimates.
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ENU administration. This is explicitly accommodated in
our model.
One might argue, on biological grounds, that the
preferred units for measuring mutation rate are ‘‘per
cell division’’ rather than ‘‘per cell per day’’ as in our
study. Although it would be interesting to estimate the
per cell division mutation rate induced by ENU treat-
ment and compare it with the spontaneous mutation
rate per cell division, there are technical difficulties with
precise determination of the number of cell divisions
during the period of ENU administration and thus
estimates of per cell division rates were not attempted in
this study. However, as opposed to base analogs, ENU,
an alkylating agent, is mutagenic regardless of whether
DNA is replicating (Snustad and Simmons 2006). By
transferring the ethyl group to oxygen or nitrogen rad-
icals at a number of reactive sites, ENU can be mutagenic
to nonreplicating DNA (Balling 2001). Thus, it is ques-
tionable whether mutation rate per cell division would
be any more informative than mutation rate per cell per
day in the case of ENU or other alkylating agents.
The waiting time until the mutant phenotype is
expressed in the liver is estimated to be 106 days (3.5
months) after ENU treatment. The estimated average
waiting time is slightly longer than the observed time of
maximum mutant frequency achieved in the liver of the
transgenic mouse carrying a bacterial transgene (1–2
months after ENU treatment) (Douglas et al. 1996;
Wang et al. 2004). In the stop-EGFP system, to exhibit
the mutant phenotype, mutant cells must express re-
vertant EGFP at a level sufficient for detection under a
fluorescence microscope. However, in bacterial transgene-
based systems such as the lacZ or lacI transgenic mouse,
mutant phenotypes are observed in an in vitro bacterial
assay system and therefore gene expression from the
mutant gene in vivo is not required for the assay (Gossen
et al. 1989; Kohler et al. 1991). Thus, it is reasonable to
speculate that more waiting time may be required to
detect a mutant phenotype from mutant cells in the
stop-EGFP system than in the lacZ or lacI transgenic
mouse.
A similar approach to that used in this study could be
applied to identify other potential mutagens or to quan-
tify their relative mutagenic effects. As well, several strains
of knockout mice with a deficient DNA repair gene have
already been generated (Winter and Gearhart 2001;
Wijnhoven and Van Steeg 2003) and rates of somatic
mutation in these strains of knockout mice could be
estimated using the stop-EGFP system after crossing the
knockout mice with stop-EGFP mice. It would also be
interesting to see whether an increase in mutation rate
(i.e., genomic instability) is observed in cancerous tissues
using the stop-EGFP mouse (Nowell 1976; Beckman
and Loeb 2006). Various types of tumors can be induced
in stop-EGFP mice by either treating them with a car-
cinogen or crossing them with tumor-prone mice such as
mice with a viral oncogene ( Jakubczak et al. 1996) or a
deficient p53 (Buettner et al. 1996). Mutation rates
then could be estimated in tumor samples and com-
pared with those of normal cells, quantifying levels of
hypermutability in various cancers.
The stop-EGFP system carrying the stop-EGFP gene
and the EBFP gene can detect all possible point mu-
tations involving base pair substitutions (BPSs). One
type of transition (AT / GC) and all types of trans-
versions (AT/ TA, AT/ CG, GC/ TA, and GC/
CG) can be detected at the premature stop codon
(TAG) of the stop-EGFP gene, while the other type of
transition (GC/ AT) can be detected at codon 66 of
the EBFP gene (see Ro and Rannala 2004). Mutations
involving insertions or deletions (‘‘indels’’) are unlikely
to be detected using this system except when a deletion
mutation removes three (or a multiple of three) nucle-
otides containing at least one nucleotide of the pre-
mature stop codon of the stop-EGFP gene. If the aim
were instead to specifically detect frameshift mutations,
a new type of ‘‘frameshifted’’ stop-EGFP gene could
instead be generated with nucleotides ½e.g., a poly(G)
tract inserted within the coding region of the func-
tional EGFP gene. A double transgenic mouse that
carries both the stop-EGFP gene and the frameshifted
EGFP gene could, in principle, be used to detect indels
or frameshift mutations as well as BPSs.
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Figure 3.—Sampling distribution of likelihood-ratio test
statistic 2 log(L1  L0) for a mutagenic effect of ENU under
the null hypothesis that ENU has no effect on mutation rate
(e.g., d ¼ 0). The histogram bars represent the sampling dis-
tribution estimated by parametric bootstrap simulations and
the smooth curve represents a x2-distribution with 1 d.f. (the
asymptotic sampling distribution). The observed value of 2
log(L1  L0) was 21.04, which is highly significant.
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